Itovebi

<p>Itovebi is a medicine used in combination with two other medicines (palbociclib and fulvestrant) to treat breast cancer when the cancer cells are ER positive and HER2-negative and have a mutation in a gene called <em>PIK3CA</em>. ER-positive means that cancer cells have receptors for oestrogen hormones on their surface and HER2-negative means that they do not have large quantities of a receptor called HER2.</p><p>Itovebi is used for cancer that is locally advanced (has spread nearby) or metastatic (has spread to other parts of the body) when the cancer has come back during or within 12 months of adjuvant hormonal treatment. An adjuvant treatment is an additional treatment given after the main treatment to lower the risk of cancer coming back.</p><p>Patients previously given a type of cancer medicine called CDK 4/6 inhibitor can be given Itovebi, in combination with palbociclib and fulvestrant, only if the cancer has come back after at least 12 months since stopping treatment with the CDK 4/6 inhibitor.</p><p>Women who have not yet reached the menopause (pre-menopausal or perimenopausal) and men should also be given a luteinising hormone-releasing hormone (LHRH) agonist (a medicine that lowers blood levels of the hormones oestrogen and progesterone).</p><p>Itovebi contains the active substance inavolisib.</p>